Phase

n/a (26,615)

phase 2 (11,933)

phase 1 (7,945)

phase 3 (6,960)

phase 4 (6,295)

phase 1/phase 2 (3,218)

phase 2/phase 3 (1,364)

early phase 1 (743)

Funder Type

Other (54,884)

Industry (20,691)

NIH (3,024)

U.S. Fed (824)

Study Type

Interventional (65,077)

Observational (12,948)

Observational [Patient Registry] (1,311)

Expanded Access (87)

Sodium-glucose cotransporter-2 inhibitor

Showing 1 - 25 of >10,000

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

MDD Trial in New York (Empagliflozin)

Not yet recruiting

Major Depressive Disorder

Empagliflozin

New York, New York

NYU Langone Health

Feb 24, 2023

Tricuspid Regurgitation Trial in Seoul (Dapagliflozin Propanediol Hydrate 12.3 mg)

Recruiting

Tricuspid Regurgitation

Dapagliflozin Propanediol Hydrate 12.3 mg

Seoul, Korea, Republic of

Samsung Medical Center

Jan 9, 2023

Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)

Completed

Fatty Liver Disease

Canagliflozin 100mg

Tainan, Taiwan

National Cheng Kung University Hospital

Feb 28, 2023

Sleep Apnea Trial in New Haven, Cleveland (Ertugliflozin 15 mg, Placebo)

Not yet recruiting

Sleep Apnea

Ertugliflozin 15 mg
Placebo

New Haven, Connecticut
+1 more

Jan 24, 2023

Second-line Therapies for Type 2 Diabetes and Moderate

Enrolling by invitation

Type 2 Diabetes
Cardiac Disease

Glucagon like peptide 1 receptor agonist
+3 more

Rochester, Minnesota

Mayo Clinic Rochester

Jan 26, 2022

Cystinuria Trial in San Francisco (Dapagliflozin)

Not yet recruiting

Cystinuria

Dapagliflozin

San Francisco, California

University of California, San Francisco

Mar 21, 2022

Heart Failure With Preserved Ejection Fraction Trial in Porto (Dapagliflozin, Spironolactone, Spironolactone + Dapagliflozin)

Recruiting

Heart Failure With Preserved Ejection Fraction

Dapagliflozin
+2 more

Porto, Portugal
+1 more

Jan 12, 2023

Diabetes, Type 2, Endothelial Dysfunction Trial in Boston (Dapagliflozin, Placebo)

Recruiting

Diabetes Mellitus, Type 2
Endothelial Dysfunction

Dapagliflozin
Placebo

Boston, Massachusetts

BU School of Medicine Evans 748

Jun 1, 2022

Glomerulonephritis, Immunoglobulin A Nephropathy Trial (Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose

Not yet recruiting

Glomerulonephritis
Immunoglobulin A Nephropathy

Corticosteroid
+2 more

(no location specified)

Oct 13, 2021

Heart Failure Trial in Glasgow (Dapagliflozin 10 MG Oral Tablet, Metolazone Tablets)

Recruiting

Heart Failure

Dapagliflozin 10 MG Oral Tablet
Metolazone Tablets

Glasgow, Strathclyde, United Kingdom
+1 more

Apr 27, 2021

Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

Not yet recruiting

Acute Kidney Injury
+2 more

Dapagliflozin 10 MG Oral Tablet [Farxiga]
Placebo

Amsterdam, Netherlands
+5 more

Oct 18, 2022

Acute Kidney Injury, Kidney Failure, Sodium Glucose Cotransporter-2 Inhibitors Trial in Newtown (SGLT2 inhibitor or matched )

Not yet recruiting

Acute Kidney Injury
+2 more

SGLT2 inhibitor or matched placebo

Newtown, New South Wales, Australia

The George Institute for Global Health

Jul 19, 2022

Renal Insufficiency, Chronic Trial in Mansoura, Tanta (Metformin, Empagliflozin, Standard therapy)

Recruiting

Renal Insufficiency, Chronic

Metformin
+2 more

Mansoura, Dakahlia Governorate, Egypt
+1 more

May 12, 2022

Diabetes, Cardiovascular Diseases Trial in Singapore (Renin-angiotensin-aldosterone system inhibitors, Beta blocker, SGLT2

Recruiting

Diabetes Mellitus
Cardiovascular Diseases

Renin-angiotensin-aldosterone system inhibitors
+2 more

Singapore, Singapore

Singapore General Hospital (SGH)

Apr 28, 2021

Fatty Liver Disease Trial (Empagliflozin 10 MG)

Not yet recruiting

Fatty Liver Disease

Empagliflozin 10 MG

(no location specified)

Jan 19, 2023

PCO Trial in Bani Suwayf (Dapagliflozin 5 MG, Metformin Hydrochloride 1000 MG, Dapagliflozin/Metformin)

Recruiting

Dapagliflozin 5 MG
+2 more

Banī Suwayf, Beni Suef, Egypt

Beni-suef university

Oct 26, 2022

Cystinuria Trial in San Francisco (Dapagliflozin)

Recruiting

Cystinuria

Dapagliflozin

San Francisco, California

University of California, San Francisco

Mar 21, 2022

Transthyretin Amyloid Cardiomyopathy Trial in New York (Empagliflozin)

Recruiting

Transthyretin Amyloid Cardiomyopathy

Empagliflozin

New York, New York

Columbia University Irving Medical Center / NewYork-Presbyterian

Mar 15, 2022

Epilepsy Trial in Saint Louis (Empagliflozin 25 mg, Placebo)

Recruiting

Epilepsy

Empagliflozin 25 mg
Placebo

Saint Louis, Missouri

Washington University

Aug 20, 2022

Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in

Completed

Diabetes Mellitus, Type 2

Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

Gentofte, Denmark
+12 more

Jan 18, 2022

CHF Trial in Moscow (Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin,

Recruiting

Congestive Heart Failure

Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)